Use of Immunomodulators and Biologics Before, During, and After Pregnancy
Authors:
- Uma MahadevanUMUma Mahadevan
- 1 January 2016
- journal article
- review article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 22 (1) , 213-223
Abstract
Immunomodulators and biologic medications, alone or in combination, form the core therapeutic strategy for managing moderate-to-severe inflammatory bowel disease (IBD). IBD incidence peaks during the prime reproductive years, raising concerns about the impact of disease and its treatment on fertility, maternal and fetal health during pregnancy, breastfeeding safety, and childhood development. Although IBD increases risk of pregnancy complications independent of disease activity, adverse pregnancy outcomes are more common when disease is active. To mitigate fetal risk, women should conceive while disease is quiescent. Aside from methotrexate, immunomodulators and biologics may be used during pregnancy to achieve and maintain disease control. Based on available safety data, there is no increased risk of congenital anomalies among infants exposed to these medications. Active thiopurine metabolites and most monoclonal antibodies cross the placenta and are detectable in neonates. They are detectable in breast milk in minute levels as well. The impact of this exposure on neonatal outcomes is discussed. Adjusted dosing schedules during gestation may reduce fetal drug exposure, though the maternal risks of such manipulation require careful consideration. Ongoing prospective studies will further inform risk assessment, including for newer medications such as the anti-integrin agents.Keywords
This publication has 116 references indexed in Scilit:
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2013
- Effects of Discontinuing Anti–Tumor Necrosis Factor Therapy During Pregnancy on the Course of Inflammatory Bowel Disease and Neonatal ExposureClinical Gastroenterology and Hepatology, 2013
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ RegistryAmerican Journal of Gastroenterology, 2012
- Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapyInflammatory Bowel Diseases, 2011
- Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006Alimentary Pharmacology & Therapeutics, 2011
- High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancyAlimentary Pharmacology & Therapeutics, 2011
- Safety of Adalimumab in Crohnʼs Disease During Pregnancy: Case Report and Review of the LiteratureInflammatory Bowel Diseases, 2010
- Adalimumab Level in Breast Milk of a Nursing MotherClinical Gastroenterology and Hepatology, 2010
- Breastfeeding and Health OutcomesBreastfeeding Medicine, 2009
- Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registriesAmerican Journal of Gastroenterology, 1998